{
    "clinical_study": {
        "@rank": "73833", 
        "arm_group": [
            {
                "arm_group_label": "Eucerin", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patient education regarding amount to be applied (amount depending on body habitus) and area of treatment field will be reinforced by the R.N. prior to the first radiation treatment. Part of patient education may involve application of the cream. Patients will be instructed to apply cream to the upper outer quadrant, upper inner quadrant, lower outer quadrant, and lower inner quadrant, as well as irradiated nodal fields. They will be instructed to apply cream in a thin, uniform layer twice a day, in the morning and evening, and not within the immediate 4 hours prior to radiation treatment. Patients will be informed that application immediately following radiation treatment is acceptable for those scheduled to receive morning treatments. Patients will be provided diaries to record the date and time they applied the study cream. Pts should return the completed diaries on their weekly status checks and at the 10-14 days following the completion of RT."
            }, 
            {
                "arm_group_label": "Mometasone Furoate 0.1%", 
                "arm_group_type": "Experimental", 
                "description": "Patient education regarding amount to be applied (amount depending on body habitus) and area of treatment field will be reinforced by the R.N. prior to the first radiation treatment. Part of patient education may involve application of the cream. Patients will be instructed to apply cream to the upper outer quadrant, upper inner quadrant, lower outer quadrant, and lower inner quadrant, as well as irradiated nodal fields. They will be instructed to apply cream in a thin, uniform layer twice a day, in the morning and evening, and not within the immediate 4 hours prior to radiation treatment. Patients will be informed that application immediately following radiation treatment is acceptable for those scheduled to receive morning treatments. Patients will be provided diaries to record the date and time they applied the study cream. Patients should return the completed diaries on their weekly status checks and at the 10-14 days following the completion of RT."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to find out if the effect of mometasone furoate is any\n      different from Eucerin in decreasing the severity of redness of the skin during irradiation,\n      preventing the skin from peeling, or reducing the amount of irritation the patient reports\n      during treatment."
        }, 
        "brief_title": "Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Invasive Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age \u226518 years\n\n          -  Stage 1-4 invasive breast cancer that is histologically confirmed at MSKCC\n\n          -  Status post mastectomy with axillary exploration (sentinel node biopsy and/or\n             axillary lymph node dissection) to receive PMRT\n\n          -  ECOG Performance Status of 0 or 1\n\n        Exclusion Criteria:\n\n          -  Male\n\n          -  Patients with clinical evidence of gross disease\n\n          -  Patients who are pregnant or breastfeeding\n\n          -  Prior radiation therapy to the ipsilateral chest wall or thorax\n\n          -  Patients requiring a chest wall boost\n\n          -  Concurrent chemotherapy (biologic agents are allowed)\n\n          -  Psychiatric illness that would prevent the patient from giving informed consent\n\n          -  Inability or unwillingness to comply with skin care instructions and follow-up\n\n          -  Allergy to either Eucerin or MF\n\n          -  Residual grade >1 skin toxicity, cellulitis, or incompletely healed wound(s) at\n             intended site of study drug application at simulation\n\n          -  Medical condition such as uncontrolled infection (including HIV), uncontrolled\n             diabetes mellitus, or connective tissue diseases (lupus, systemic sclerosis, or other\n             collagen vascular diseases)\n\n          -  Treatment with non-standard, inverse-planned Intensity Modulated Radiation Therapy\n             (IMRT), palliative or pre-operative radiation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "143", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01856543", 
            "org_study_id": "13-069"
        }, 
        "intervention": [
            {
                "arm_group_label": "Eucerin", 
                "intervention_name": "Eucerin", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Mometasone Furoate 0.1%", 
                "intervention_name": "Mometasone Furoate 0.1%", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Mometasone furoate"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Breast cancer", 
            "Status post mastectomy", 
            "plan to receive PMRT", 
            "Topical", 
            "steroid cream", 
            "emollient skin care", 
            "Eucerin", 
            "Mometasone Furoate 0.1%"
        ], 
        "lastchanged_date": "March 24, 2014", 
        "link": {
            "description": "Memorial Sloan-Kettering Cancer Center", 
            "url": "http://www.mskcc.org/"
        }, 
        "location": [
            {
                "contact": {
                    "last_name": "Molly Olm-Shipman, RN", 
                    "phone": "212-639-8686"
                }, 
                "facility": {
                    "address": {
                        "city": "Basking Ridge", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07939"
                    }, 
                    "name": "Memorial Sloan-Kettering Cancer Center at Basking Ridge"
                }, 
                "investigator": {
                    "last_name": "Molly Olm-Shipman, RN", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Molly Olm-Shipman, RN", 
                    "phone": "212-639-8686"
                }, 
                "contact_backup": {
                    "last_name": "Alice Ho, MD", 
                    "phone": "212-639-6773"
                }, 
                "facility": {
                    "address": {
                        "city": "Commack", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11725"
                    }, 
                    "name": "Memorial Sloan-Kettering Cancer Center @ Commack"
                }, 
                "investigator": {
                    "last_name": "Molly Olm-Shipman, RN", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Molly Olm-Shipman, RN", 
                    "phone": "212-639-8686"
                }, 
                "contact_backup": {
                    "last_name": "Alice Ho, MD", 
                    "phone": "212-639-6773"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Memorial Sloan Kettering Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Molly Olm-Shipman, RN", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Molly Olm-Shipman, RN", 
                    "phone": "212-639-8686"
                }, 
                "facility": {
                    "address": {
                        "city": "Rockville Centre", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11570"
                    }, 
                    "name": "Memorial Sloan-Kettering Cancer Center at Mercy Medical Center"
                }, 
                "investigator": {
                    "last_name": "Molly Olm-Shipman, RN", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Molly Olm-Shipman, RN", 
                    "phone": "212-639-8686"
                }, 
                "facility": {
                    "address": {
                        "city": "Sleepy Hollow", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10591"
                    }, 
                    "name": "Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center"
                }, 
                "investigator": {
                    "last_name": "Molly Olm-Shipman, RN", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation:A Randomized Trial, Double Blind Trial", 
        "overall_contact": {
            "last_name": "Molly Olm-Shipman, RN", 
            "phone": "212-639-8686"
        }, 
        "overall_contact_backup": {
            "last_name": "Alice Ho, MD", 
            "phone": "212-639-6773"
        }, 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "Molly Olm-Shipman, RN", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Skin toxicity assessments and assessment of patient-reported compliance will be done on a weekly basis while the patient is receiving RT, by the RN or physician utilizing CTCAE 4.0 and the weekly status check form, as per current standard practice.", 
            "measure": "skin toxicity", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01856543"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "will be measured using the Skindex-16 assessment tool. Clinician will assess the patients' Fitzpatrick Skin Category.", 
            "measure": "Patient-reported skin toxicities", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "source": "Memorial Sloan-Kettering Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}